ClinicalTrials.gg
RecruitingNCT05733416INCOGNITOUpdated Oct 15, 2026

Intensive Cancer Screening After Cryptogenic Stroke

An interventional study of FDG PET/CT and Usual Care in Occult Cancer, sponsored by Ottawa Hospital Research Institute. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Ottawa Hospital Research Institute · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.
Updated Oct 15, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 117 studies in Ischemic Stroke with a site in Canada — 32 open to participants now, 39 under way, 9 of them phase 3. Ischemic Stroke · Canada.

Planned enrollment
78th of 90
45 · median 275
Started
2023
with 8 others
No phase
40 of 117
12 open now
Primary completion
2028-01
later than 21 of 38 live
Registered
91st of 117
by date
Lead sponsor
3 of 117
Ottawa Hospital Research Institute

Among the 117 studies in Ischemic Stroke with a site in Canada, this one is the 78th largest by planned enrollment of the 90 interventional ones that give a count, is one of 9 that started in 2023, is one of 40 with no phase, reaches primary completion later than 21 of the 38 other live ones, and was the 91st registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

32 of the 117 studies in Ischemic Stroke with a site in Canada are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 117 studies in Ischemic Stroke with a site in Canada, or all of them as a file.
02

Study summary

The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT (F-fluorodeoxyglucose positron emission/computed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.

03

Conditions studied

  • Occult Cancer

Browse trials for

Keywords

  • cryptogenic stroke
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults ≥18 years
  • presenting to the Ottawa Hospital Stroke Prevention Clinic or the Ottawa Hospital Neurovascular Unit with a first cryptogenic ischemic stroke after advanced evaluation as per American Heart Association guidelines and Saver approach (maximum 3 months after stroke)
  • patient or delegate willing and able to provide .

Exclusion criteria

Exclusion Criteria:

  • to FDG PET/CT (pregnancy or unable to lie still in bed for 20 minutes)
  • active cancer or previous cancer diagnosis (other than basal or squamous cell carcinoma of the skin)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Intensive Cancer Screening

    Usual care plus FDG PET/CT

    Diagnostic Test: FDG PET/CT

  • Other
    Usual Care

    Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care)

    Diagnostic Test: Usual Care

Interventions

  • Diagnostic testFDG PET/CT

    F-fluorodeoxyglucose positron emission/computed tomography

  • Diagnostic testUsual Care

    Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care

06

What researchers measure

Primary outcomes

  1. Participant Recruitment

    Number of participants recruited

    Time frame: Over 12 months

Secondary outcomes

  1. Eligibility Rate

    percentage of screened patients who are eligible

    Time frame: Over 12 months

  2. Consent Rate

    percentage of eligible patients who provide consent

    Time frame: Over 12 months

  3. Retention Rate

    percentage of participants retained at follow-up

    Time frame: Over 24 months

  4. Study Completion Rate

    percentage of participants who completed all study procedures

    Time frame: Over 24 months

  5. Adherence Rate

    adherence to screening strategy

    Time frame: Over 24 months

Other outcomes

  1. Screening time frame

    time from diagnosis to screening

    Time frame: Over 24 months

  2. Reasons for participation

    Reasons for accepting/declining participation

    Time frame: Over 24 months

  3. Usual care cancer screening strategies

    Usual care cancer screening strategies ordered by treating physicians

    Time frame: Over 24 months

07

Study locations

2 of 3 sites recruiting
  • Calgary Foothills Medical Centre
    Calgary, Alberta T2N 2T9, Canada
    Not yet recruiting
  • The Ottawa Hospital
    Ottawa, Ontario K1Y 4E9, Canada
    Recruiting
    • Michele Demetroff · Contactmdemetrof@ohri.ca · 6137985555
    • Dariush Dowlatshahi, MD PhD · Principal investigator
    • Deborah Siegal, MD · Principal investigator
  • Centre Hospitalier de l'Université de Montréal
    Montreal, Quebec H2X 0C1, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Jan 2028, 52 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 52 months is above that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jan 2027 → Jan 2028 and completion Jan 2027 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2023
First posted
Feb 17, 2023
StartActual
Sep 1, 2023
Primary completionEst.
Jan 2028was Jan 2027
CompletionEst.
Jan 2028was Jan 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 Canada)
  • Calgary Foothills Medical Centre · Calgary, Canada
  • Centre Hospitalier de l'Université de Montréal · Montreal, Canada
Oct 15, 2026
Primary completion
Jan 2027→Jan 2028
Oct 15, 2026
Study completion
Jan 2027→Jan 2028
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    2 sites added
    Show 2 added (2 Canada)
    • Calgary Foothills Medical Centre · Calgary, Canada
    • Centre Hospitalier de l'Université de Montréal · Montreal, Canada
    Primary completion Jan 2027→Jan 2028
    Study completion Jan 2027→Jan 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05733416
Collaborators
Brain Canada, Heart and Stroke Foundation of Canada, Canadian Stroke Consortium (CSC)
Responsible party
Sponsor
First posted
Feb 17, 2023
Start date
Sep 1, 2023
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Dariush Dowlatshahi, MD PhD
Contact
ddowlat@toh.ca
613-798-5555 ext. 14709
Deborah Siegal, MD
Contact
dsiegal@toh.ca
613-737-8899 ext. 78060
Dariush Dowlatshahi, MD PhD
principal investigator · Ottawa Hospital Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion